Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y W Stevens

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Advances in Experimental Medicine and Biology|January 1, 1986
"Defective" receptors in steroid-resistant conditions may be proteolytic artifactsM R Sherman, F B Tuazon, Y W Stevens, et al.
Cancer Research|January 1, 1981
Immunochemical differences between glucocorticoid receptors from corticoid-sensitive and -resistant malignant lymphocytesJ Stevens, H J Eisen, Y W Stevens, et al.
Toxicology and Industrial Health|March 11, 2000
Agency for Toxic Substances and Disease Registry's 1997 priority list of hazardous substances. Latent effects--carcinogenesis, neurotoxicology, and developmental deficits in humans and animalsS R Ostrowski, S Wilbur, C H Chou, et al.
Cancer Research|January 15, 1989
4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemiaE Berman, V Raymond, A Daghestani, et al.
Cancer Research|February 15, 1990
Phase I clinical and pharmacological study of merbaroneJ J Dimaggio, R P Warrell, J Muindi, et al.
Cancer Research|December 15, 1988
Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervalsC W Young, M P Fanucchi, T Declan Walsh, et al.
Toxicology and Industrial Health|November 1, 1993
The Agency for Toxic Substances and Disease Registry's role in development and application of biomarkers in public health practiceC T Derosa, Y W Stevens, J D Wilson, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Advances in Experimental Medicine and Biology|January 1, 1986
"Defective" receptors in steroid-resistant conditions may be proteolytic artifactsM R Sherman, F B Tuazon, Y W Stevens, et al.
Cancer Research|January 1, 1981
Immunochemical differences between glucocorticoid receptors from corticoid-sensitive and -resistant malignant lymphocytesJ Stevens, H J Eisen, Y W Stevens, et al.
Toxicology and Industrial Health|March 11, 2000
Agency for Toxic Substances and Disease Registry's 1997 priority list of hazardous substances. Latent effects--carcinogenesis, neurotoxicology, and developmental deficits in humans and animalsS R Ostrowski, S Wilbur, C H Chou, et al.
Cancer Research|January 15, 1989
4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemiaE Berman, V Raymond, A Daghestani, et al.
Cancer Research|February 15, 1990
Phase I clinical and pharmacological study of merbaroneJ J Dimaggio, R P Warrell, J Muindi, et al.
Cancer Research|December 15, 1988
Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervalsC W Young, M P Fanucchi, T Declan Walsh, et al.
Toxicology and Industrial Health|November 1, 1993
The Agency for Toxic Substances and Disease Registry's role in development and application of biomarkers in public health practiceC T Derosa, Y W Stevens, J D Wilson, et al.
Pageof 2